GlassScriptPhysician profile
Andrew Azadian
NPI 1215272125
$5,795.00
in general payments reported to CMS, 2019-2025
20 companies · $3,224 in 2025
The $3,224 reported for 2025 was more than what 97% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $337 · 2022: $87.61 · 2023: $1,179 · 2024: $968 · 2025: $3,224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,234 · Travel and Lodging: $1,136.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,234.31 |
| Travel and Lodging | $1,135.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $3,480.39 | 2023-2025 | Barostim Neo System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $549.08 | 2021-2025 | Lifevest |
| Impulse Dynamics (USA) INC. | $422.37 | 2023-2024 | Optimizer, Optimizer |
| Alnylam Pharmaceuticals INC. | $202.35 | 2024-2025 | Amvuttra, Onpattro |
| Merck Sharp & Dohme LLC | $178.18 | 2023-2025 | Verquvo, Keytruda |
| Novartis Pharmaceuticals Corporation | $159.30 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $155.90 | 2021-2025 | Lokelma, Wainua |
| Itamar Medical INC | $145.87 | 2023 | Watchpatone |
| Edwards Lifesciences Corporation | $142.14 | 2025 | |
| Amgen INC. | $56.21 | 2023-2025 | Repatha, Repatha |
| Novo Nordisk INC | $48.84 | 2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $47.52 | 2025 | Evkeeza |
| Scpharmaceuticals INC. | $46.70 | 2025 | |
| Abiomed | $29.87 | 2024 | Impella |
| Incyte Corporation | $27.11 | 2025 | Zynyz |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bridgebio Pharma, INC. | $27.06 | 2025 | Attruby |
| Puma Biotechnology, INC. | $20.34 | 2025 | |
| Esperion Therapeutics, INC. | $19.12 | 2025 | Nexletol |
| Boston Scientific Corporation | $18.80 | 2025 | Lux-Dx Insertable Cardiac Monitor |
| Pfizer INC. | $17.85 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Azadian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.